temporal

A group of international and multidisciplinary clinical experts and Patient Advocacy Group representatives conducted a survey to investigate screening, therapeutic strategies and patient journeys of hepatocellular cancer (HCC) across the Asia Pacific region. These findings were presented at the poster tour at the opening ceremony of ILCA.

As liver cancer is the leading cause of cancer deaths in several Asian countries, these data can provide insight into the national approach to HCC management for each country, potential areas for improvement, and what to prioritise to shape national policies to improve outcomes for patients.

Clinical Takeaways

  • The awareness of risk factors related to HCC should be increased among both primary care providers and the general Asian population
  • Healthcare practitioners should monitor and manage treatment side effects, maintain a strong communication with patients and deploy trained nurses or case managers in the healthcare team to enhance patient education and support throughout the HCC patient journey
  • There is a need to improve patient access to HCC treatment options known to extend survival rates, such as atezolizumab + bevacizumab

 

Authors

Prof. Rosmawati Mohamed*1, Wendy Wang*2, Tawesak Tanwandee3, Irsan Hasan4, Phuong Pham Cam5, Young-Suk Lim6, Sheng-Nan Lu7, Munisamy Murallitharan8, Huong Tran Thi Thanh9, Evy Ratnawati10, Wattana Sukeepaisarnjaroen11, Mahir Karababa12, Prof. Chee-Kiat Tan13

 

1University of Malaya, Kuala Lumpur, Malaysia; 2Liver Disease Prevention and Treatment Research Foundation, Taiwan; 3Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 4Faculty of Medicine, University Indonesia/Ciptomangunkusumo Hospital, Indonesia; 5Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, and Department of Nuclear Medicine, Ha Noi Medical University, Hanoi, Vietnam; 6Department of Internal Medicine and Department of Gastroenterology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Republic of Korea; 7Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan; 8National Cancer Society of Malaysia, Jalan Raja Muda Abdul Aziz, Wilayah Persekutuan Kuala Lumpur, Malaysia; 9National Cancer Institute, Hanoi, and Vietnam and Hanoi Medical University, Hanoi, Vietnam; 10Indonesian Cancer Information and Support Center (CISC), Indonesia; 11Faculty of Medicine, Khon Kaen University, Khon Kaen, Changwat Khon Kaen, Thailand; 12COR2ED, Basel, Switzerland; 13Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore

Programme summary
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Roche.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HCC CONNECT

HCC CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Video
Oncology 
The evolving role of liquid biopsy in biomarker testing

Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer

Experts
Assoc. Prof. Umberto Malapelle
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
Advanced renal cell carcinoma: Managing a long-term durable response

Maximising outcomes for patients with advanced RCC 

Experts
Prof. Michael Staehler
Endorsed by
Urobel VZW | ASBL
  • clock 15 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Eisai Europe Limited.
Other

Episode

1

of 1

episode
Oncology 
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.